Issue Date: January 16, 2017 | Web Date: January 12, 2017
Healthcare conference brings deal deluge
As has become traditional, the annual J.P. Morgan Healthcare Conference kicked off in San Francisco last week with a flurry of pharmaceutical deal-making. But the party was interrupted two days later when President-elect Donald Trump unexpectedly slammed the industry.
The biggest deal of the week was Takeda Pharmaceuticals’ $5.2 billion purchase of cancer drug developer Ariad Pharmaceuticals. Takeda gains the rights to Iclusig, already approved to treat two types of blood cancer, and brigatinib, an . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society